Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI

Annie (Annie) T. Packard

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Endometriosis

Treatments: Drug: F-18 FES

Study type: Interventional

Funder types: Other

Identifiers

NCT04347135

19-004345

Details and patient eligibility

About

Researchers are trying to improve the detection of endometriosis using F-18 FES PET/MRI imaging.

Sex: Female

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Premenopausal women (18-50) with endometriosis

Exclusion criteria

• Postmenopausal women
• AP diameter when lying supine greater than 32 cm (too large for PET/MRI)
• Unable to undergo PET/MRI for any reason (metal implants, severe claustrophobia)
• Unable to receive IV Gadolinium contrast for any reason (renal failure eGFR < 60, contrast allergy)
• Pregnant (Urine test will be provided for all patients)

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

F-18 FES PET/MRI

Experimental group

Description:

16α-(18)F-fluoro-17β-estradiol (\[F-18\] FES)

Treatment:

Drug: F-18 FES